Cargando...
Targeting the mTOR kinase domain: the second generation of mTOR inhibitors
The mTOR signaling pathway is dysregulated in ~50% of all human malignancies and is a major cancer drug target. Although rapamycin analogs (rapalogs) have shown clinical efficacy in a subset of cancers, they do not fully exploit the antitumor potential of mTOR targeting. Because the mTOR kinase doma...
Gardado en:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2011
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3073023/ https://ncbi.nlm.nih.gov/pubmed/21333749 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.drudis.2011.02.008 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|